- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03610035
A Study of NPT189 in Healthy Subjects
August 14, 2019 updated by: Proclara Biosciences, Inc.
A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of NPT189 in Healthy Subjects
The purpose of the study is to evaluate the safety and tolerability of single dose of NPT189 in healthy volunteers.
The study will also evaluate the pharmacokinetic characteristics of NPT189.
Study Overview
Detailed Description
This study is a Phase1, randomized, double-blind, placebo-controlled, single dose, dose escalation safety and tolerability study of NPT189 in health subjects.
Six dose cohorts are planned each with a maximum of 8 participants per cohort.
Participants will receive NPT189 by intravenous (IV) or a matching placebo by intravenous infusion.
Safety, tolerability, and pharmacokinetics will be assessed.
Study Type
Interventional
Enrollment (Actual)
48
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Groningen, Netherlands, 9728 NZ
- PRA Health Sciences
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female subjects between the ages of 18 and 65 years (inclusive);
- Has provided written informed consent to participate in the study;
- Weigh ≥ 45kg and ≤ 120kg with Body Mass Index of 18-32 inclusive;
- Subject Rescreening: This study does not permit the re-enrollment of a subject who has discontinued from the study as a pre-treatment failure without approval from the sponsor unless the reason they were not included was because the required number of subjects needed at the time of randomization had already been met. Rescreened subjects must continue to meet all inclusion and exclusion criteria. All screening procedures must be performed within 28 days of dose administration
- Female subjects of childbearing potential (defined as not surgically sterile or at least two years postmenopausal confirmed by a Screening Follicle Stimulating Hormone (FSH) level of > 40) must agree to use one of the following forms of contraception from 60 days prior through 90 days following the dose of Study Drug: hormonal (oral, transdermal, implant, or injection), barrier (condom, diaphragm with spermicide), intrauterine device (IUD), complete abstinence, or vasectomized partner (6 months minimum) or male subjects who are sexually active with women of child-bearing potential must agree to complete abstinence or to use a condom for 90 days following the dose of Study Drug;
- No clinically significant abnormal findings on physical examination, vital signs, ECG, or clinical laboratory evaluation during screening; and systolic blood pressure between 140 mm and 90 mm Hg and diastolic blood pressure between 90 mm and 45 mm Hg.
- Can understand and sign the informed consent document, can communicate with the investigator, and can understand and comply with the requirements of the protocol.
Exclusion Criteria:
- Have a past or present serious medical illness or other medical or social reason that in the opinion of the Principal Investigator, would jeopardize the safety of the subject or impact the validity of the study results;
- Participation in a clinical trial (other than a screening visit) within 60 days of study drug administration;
- Use of any over-the-counter or prescription medication within 14 days prior to the dose of Study Drug or during the study, with the exception of hormonal contraceptives for women of childbearing potential, unless approved by the Principal Investigator or use of beta-blockers within 30 days prior to dose of Study Drug or during the study;
- Donation of blood or plasma within 30 days of the dose of Study Drug and throughout the duration of the study and for male subjects, donation of sperm through the duration of the study;
- Women who are nursing, pregnant, suspected of being pregnant, or trying to become pregnant, or are lactating, have a positive serum pregnancy test at screening or urine pregnancy test prior to administration of Study Drug regardless of childbearing potential;
- Positive blood screen for HIV, hepatitis B surface antigen (HbSAg), or hepatitis C as Screening, or a positive urine screen for alcohol (Day -1 only) or, drugs of abuse, or cotinine at Screening and on Day -1;
- Have clinically significant abnormalities in laboratory values as judged by the clinical investigator;
- Have a history of alcoholism and/or drug abuse;
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo Comparator
Placebo
|
Placebo
|
Experimental: Experimental
NPT189
|
IgG1 Fc-GAIM fusion protein, a recombinant fusion protein
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of a single intravenous (IV) infusion of NPT189 (subjects experiencing adverse events)
Time Frame: Day 1 through to Day 49
|
Summary of the frequency and percentage of
|
Day 1 through to Day 49
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Profile of pharmacokinetics (PK) of a single intravenous (IV) infusion of NPT189 (Cmax)
Time Frame: Day 1 through to Day 49
|
Observed maximum concentration (Cmax)
|
Day 1 through to Day 49
|
Profile of pharmacokinetics (PK) of a single intravenous (IV) infusion of NPT189 (Tmax)
Time Frame: Day 1 through to Day 49
|
Time of the maximum measured concentration (Tmax)
|
Day 1 through to Day 49
|
Profile of pharmacokinetics (PK) of a single intravenous (IV) infusion of NPT189 (AUClast)
Time Frame: Day 1 through to Day 49
|
Area under the concentration-time curve from time zero to the last quantifiable concentration time-point (AUClast)
|
Day 1 through to Day 49
|
Profile of pharmacokinetics (PK) of a single intravenous (IV) infusion of NPT189 (AUCinf)
Time Frame: Day 1 through to Day 49
|
Area under the concentration-time curve from time zero extrapolated to infinity (AUCinf)
|
Day 1 through to Day 49
|
Profile of pharmacokinetics (PK) of a single intravenous (IV) infusion of NPT189. Terminal elimination half-life (t 1/2)
Time Frame: Day 1 through to Day 49
|
Terminal elimination half-life (t 1/2)
|
Day 1 through to Day 49
|
Profile of pharmacokinetics (PK) of a single intravenous (IV) infusion of NPT189. Clearance (CL)
Time Frame: Day 1 through to Day 49
|
Clearance (CL)
|
Day 1 through to Day 49
|
Profile of pharmacokinetics (PK) of a single intravenous (IV) infusion of NPT189. Volume of distribution (Vd)
Time Frame: Day 1 through to Day 49
|
Apparent volume of distribution (Vd)
|
Day 1 through to Day 49
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Proclara Biosciences, Proclara
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 24, 2018
Primary Completion (Actual)
February 17, 2019
Study Completion (Actual)
February 17, 2019
Study Registration Dates
First Submitted
July 16, 2018
First Submitted That Met QC Criteria
July 26, 2018
First Posted (Actual)
August 1, 2018
Study Record Updates
Last Update Posted (Actual)
August 15, 2019
Last Update Submitted That Met QC Criteria
August 14, 2019
Last Verified
December 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NPT189-CL001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Amyloidosis
-
Millennium Pharmaceuticals, Inc.CompletedLight-Chain AmyloidosisUnited States, Canada, France, Germany, Italy
-
Boston UniversityCorino Therapeutics, Inc.CompletedTransthyretin Amyloidosis | Amyloidosis, Leptomeningeal, Transthyretin-RelatedUnited States
-
Chulalongkorn UniversityUnknown
-
Criterium, Inc.AmgenCompletedAmyloidosis | Systemic Light Chain AmyloidosisUnited States
-
Steen Hvitfeldt PoulsenRecruitingTransthyretin Amyloidosis | Transthyretin Cardiac Amyloidosis | Wild-Type Transthyretin-Related (ATTR)AmyloidosisDenmark
-
Peking Union Medical College HospitalXian-Janssen Pharmaceutical Ltd.Active, not recruitingAmyloidosis; SystemicChina
-
IRCCS Policlinico S. MatteoRecruiting
-
University Hospital Center of MartiniqueTerminated
-
Kaneka Medical America LLCRecruitingDialysis AmyloidosisUnited States
-
Peking Union Medical College HospitalRecruitingLight Chain (AL) Amyloidosis | Venetoclax | CCND1 TranslocationChina
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States